In contrast, another study by Jiang et al. reported that multiple myeloma patients with a higher ZHX2 expression showed poorer clinical outcomes, and the knockdown of ZHX2 in cancer cells caused MM cells to be more sensitive to Bortezomib (BTZ) by regulating the nuclear translocation of NF-κB, also affecting NF-κB and the corresponding target genes’ expression at the mRNA levels [55]. This evidence concerns the gene ZHX2 and Miyoshi myopathy.